Last updated on September 2018

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies

Clinical Study Identifier: NCT02006485

Contact Investigators or Research Sites near you

Start Over

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Huntsville, AL United States

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Jonesboro, AR United States

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Duarte, CA United States

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Atlanta, GA United States

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Omaha, NE United States

Nathan Fowler, MD

MD Anderson Cancer Center
Houston, TX United States